Seminars in Diagnostic Pathology
Volume 23, Issue 2 , Pages 84-90 , May 2006

GIST under imatinib therapy

  • Raf Sciot, MD, PhD

      Affiliations

    • Department of Pathology, University Hospital, Catholic University of Leuven, Leuven, Belgium
    • Corresponding Author InformationAddress reprint requests and correspondence: Raf Sciot, MD, PhD, Department of Pathology, University Hospital St. Rafaël, Minderbroedersstraat 12, B-3000 Leuven, Belgium.
    • ,
  • Maria Debiec-Rychter, MD

      Affiliations

    • Department of Human Genetics, University Hospital, Catholic University of Leuven, Leuven, Belgium.

References 

  1. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;1052:1052–1056
  2. Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours (A phase I study). Lancet. 2001;358:1421–1423
  3. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480
  4. Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol. 2003;22:814
  5. Debiec-Rychter M, Dumez H, Judson J, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004;40:689–695
  6. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–1134
  7. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093–1103
  8. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the managament of gastrointestinal stromal tumors (Report of the GIST consensus conference of 20-21 March 2004, under the auspices of ESMO). Ann Oncol. 2005;16:566–578
  9. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–4349
  10. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol. 2006;59:557–563
  11. Blanke CD, Demitri GD, Von Mehren MC, et al. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. J Clin Oncol. 2006;24:9528
  12. Bauer S, Hartmann JT, de Wit M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer. 2005;117:316–325
  13. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182–4190
  14. Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with “unresectable” cKit+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg. 2003;186:665–669
  15. Chacon M, Roca E, Huertas E, et al. CASE 3 (Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate). J Clin Oncol. 2005;23:1580–1582
  16. Melichar B, Voboril Z, Nozicka J, et al. Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy. Intern Med. 2005;44:1163–1168
  17. Hogenauer C, Langner C, Lipp RW, et al. Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI571): effect of low dosage in an advanced tumour with exon 11 mutation. Eur J Gastroenterol Hepatol. 2003;15:323–327
  18. Bauer S, Lang H, Schutte J, et al. Complete remission with imatinib in metastatic gastrointestinal stromal tumors. J Clin Oncol. 2005;23:6800–6801
  19. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23:1–8
  20. Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004;23:3999–4006
  21. Trent JC, Choi K, Hunt H, et al. Apoptotic and anti-vascular activity of imatinib in GIST patients. J Clin Oncol. 2005;23:9001
  22. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004;15:275–286
  23. Bagley RG, Weber W, Rouleau C, et al. Pericytes and endothelial precursor cells: cellular interactions and contributions to malignanacy. Cancer Res. 2005;65:9741–9750
  24. Song S, Ewald AJ, Stallcup W, et al. PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol. 2005;7:870–879
  25. Seandal M, Shia J, Linkov I, et al. The activity of sunitinib (SU11248) against gastrointestinal stromal tumor (GIST) appears to be distinct from its anti-angiogenic effects. Clin Cancer Res. 2006;in press
  26. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128:270–279
  27. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005;6:249–251
  28. Fletcher JA, Corless CL, Dimitrijevic S, et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2003;22:815
  29. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12:1743–1749
  30. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004;64:5913–5919
  31. Grimpen F, Yip D, McArthur G, et al. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol. 2005;6:724–727
  32. Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquiered resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology. 2004;127:294–299
  33. Tamborini E, Pricl S, Negri T, et al: Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene (online June 2006)
  34. Wakai T, Kanada T, Hirota S, et al. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer. 2004;90:2059–2061
  35. Heinrich MC, Mali RG, Corless CL, et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol. 2006;24:9502
  36. Pauwels P, Debiec-Rychter M, Stul M, et al. Changing phenotype of gastrointestinal stromal tumors under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology. 2005;47:41–47

PII: S0740-2570(06)00141-9

doi: 10.1053/j.semdp.2006.08.005

Seminars in Diagnostic Pathology
Volume 23, Issue 2 , Pages 84-90 , May 2006

Article Tools

* Image Usage & Resolution